

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.


Dated: June 24, 2002

Signature: Shawn P. Foley
(Shawn P. Foley)

Docket No.: EGYPT 3.0-015
(PATENT)

1645

#15



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Colas et al.

Application No.: 10/066,965

Group Art Unit: 1645

Filed: November 13, 2001

Examiner: Not Yet Assigned

For: TARGETED MODIFICATION OF
INTRACELLULAR COMPOUNDS

Commissioner for Patents
Washington, DC 20231

RECEIVED

JUL 3 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference is enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: June 24, 2002

Respectfully submitted,

By Shawn P. Foley
Shawn P. Foley
Registration No.: 33,071
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorneys for Applicant



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/066,965
				Filing Date	November 13, 2001
				First Named Inventor	Pierre Colas
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	EGYP 3.0-015

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

JUL 3 2002

TECH CENTER 1600/2900



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	10/066,965		
		Filing Date	November 13, 2001		
		First Named Inventor	Pierre Colas		
		Group Art Unit	1645		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	EGYP 3.0-015

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	WILSON et al. "Cells that register logical relationships among proteins," 94 Proc. Natl. Acad. Sci. USA (1997) 12473-78.	
	CB	COLAS & BRENT, "The impact of two-hybrid and related methods on biotechnology," TIBTECH vol. 16, (August 1998) 355-63.	
	CC	FABBRIZIO et al., "Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity," 18 Oncogene (1999) 4357-63.	
	CD	GEYER et al. "Mutagenesis" by peptide aptamers identifies genetic network members and pathway connections," 96 Proc. Natl. Acad. Sci. USA (1999) 8567-72.	
	CE	ESTOJAK et al., "Correlation of Two-Hybrid Affinity Data with In Vitro Measurements," 15 Mol. Biol. Cell. Biol. (1995) 5820-29.	
	CF	HUIBREGTSE et al "A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase," 92 Proc. Natl. Acad. Sci. USA (1995) 2563-67.	
	CG	SILVER et al., "DNA binding is not sufficient for nuclear localization of regulatory proteins in saccharomyces cerevisiae," 6 Mol. Cell. Biol. (1986) 4763-66.	
	CH	MAHANTY et al. "Nuclear shuttling of yeast scaffold Ste5 is required for its recruitment to the plasma membrane and activation of the mating MAPK cascade," 98 Cell (1999) 501-12.	
	CI	WANG et al. "Functional Domains of the Rsp5 Ubiquitin-Protein Ligase," 19 Mol. Cell Biol. (1999) 342-52.	
	CJ	GOSINK & VIERSTRA "Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes," 92 Proc. Natl. Acad. Sci. USA (1995) 9117-21.	
	CK	SCHNEIDER et al. "Mutagenesis and selection of PDZ domains that bind new protein targets," 17 Nature Biotechnology (1999) 170-175.	
	CL	BEERLI et al. "Intracellular expression of single chain antibodies reverts ErbB-2 transformation," 269 J. Bio. Chem. (1994) 23931-36.	
	CM	ZHOU et al. "Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins," 6 Mol. Cell. (2000) 751-56.	
	CN	COHEN et al. "An artificial cell-cycle inhibitor isolated from a combinatorial library," 95 Proc. Natl. Acad. Sci. USA (1998) 14272-77.	
	CO	PIERRE COLAS "Combinatorial protein reagents to manipulate protein function," 4 Current Opinion in Chem. Biol. (2000) 54-59.	
	CP	COLAS et al. "Gentic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2," 380 Nature (1996) 548-550.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED
JUL 3 2002
TECH CENTER 1600/2900